# obesity
Latest news and articles about obesity
Total: 4 articles found
Chinese Drugmaker Wins FDA Green Light to Test Next‑Generation Obesity Peptide in the US
Shiyao Group has won FDA permission to begin US clinical trials of a long‑acting peptide that acts on both GLP‑1 and GIP receptors for weight management in people with obesity or overweight plus comorbidities. The clearance permits investigational trials but falls short of marketing approval; success would boost China’s ambitions to compete in the lucrative obesity‑drug market dominated by Western firms.
Activating a Brain Circuit Slashes Fat in Mice — A Promising But Distant Route to Treating Obesity
Researchers at Washington University found that activating a specific brain‑originating neural pathway rapidly reduced whole‑body fat in mice without dietary change, a result published in Nature Metabolism. The finding highlights a potential central mechanism for controlling adiposity, but major translational, safety and ethical hurdles remain before human therapies could emerge.
Pfizer’s Monthly GLP‑1 Shows Promising Weight‑Loss Signal — A New Challenger in a Crowded Market
Pfizer’s long‑acting GLP‑1 candidate PF‑08653944 produced a 12.3% placebo‑adjusted mean weight loss at 28 weeks and sustained reductions after switching to monthly dosing, with mainly mild‑to‑moderate gastrointestinal side effects. The company has launched an ambitious phase 3 programme of ten trials and plans to advance full development in 2026, positioning itself to challenge incumbent GLP‑1 therapies if larger trials confirm efficacy and safety.
Chinese Drugmaker Huadong Advances RNAi Weight‑loss Candidate into Preclinical Studies
Huadong Medicine and Suzhou Shian Biotech have confirmed a preclinical siRNA candidate aimed at an innovative weight‑loss mechanism and entered preclinical research. The move underscores China’s push into RNAi therapeutics for metabolic disease, but substantial scientific, delivery and regulatory challenges lie ahead before any clinical testing.